ALDH2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignancies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
ALDH2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignancies ; volume:21 ; number:1 ; day:22 ; month:5 ; year:2021 ; pages:1-11 ; date:12.2021
BMC cancer ; 21, Heft 1 (22.5.2021), 1-11, 12.2021
- Urheber
-
Matsumoto, Akiko
Nakashima, Chiho
Kimura, Shinya
Sueoka, Eizaburo
Aragane, Naoko
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-021-08329-y
- URN
-
urn:nbn:de:101:1-2021091919510556479947
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:38 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Matsumoto, Akiko
- Nakashima, Chiho
- Kimura, Shinya
- Sueoka, Eizaburo
- Aragane, Naoko
- SpringerLink (Online service)
Ähnliche Objekte (12)
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Regulatory mechanisms of PD-1/PD-L1 in cancers
The PD-1:PD-L1 axis in Inflammatory Arthritis
PD-1/PD-L1 binding studies using microscale thermophoresis
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Regulatory mechanisms of PD-1/PD-L1 in cancers
The PD-1:PD-L1 axis in Inflammatory Arthritis
PD-1/PD-L1 binding studies using microscale thermophoresis
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Regulatory mechanisms of PD-1/PD-L1 in cancers
The PD-1:PD-L1 axis in Inflammatory Arthritis
PD-1/PD-L1 binding studies using microscale thermophoresis
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors